Centessa Pharmaceuticals plc
NASDAQ:CNTA
17.16 (USD) • At close December 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 6.853 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.131 | 0.034 | 0 | 0 |
| Gross Profit
| 6.853 | -0.131 | -0.034 | 0 | 0 |
| Gross Profit Ratio
| 1 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 124.405 | 155.083 | 96.311 | 9.301 | 4.263 |
| General & Administrative Expenses
| 53.731 | 55.2 | 43.009 | 1.139 | 0.79 |
| Selling & Marketing Expenses
| 0 | 0 | 42.927 | 0 | 0 |
| SG&A
| 53.731 | 55.2 | 42.97 | 1.139 | 0.79 |
| Other Expenses
| 0 | 2.342 | 0 | 0.155 | 0.105 |
| Operating Expenses
| 178.136 | 210.283 | 139.28 | 10.44 | 5.053 |
| Operating Income
| -171.283 | -212.263 | -139.314 | -10.44 | -5.053 |
| Operating Income Ratio
| -24.994 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -4.858 | -4.691 | -6.874 | -0.223 | -0.008 |
| Income Before Tax
| -176.141 | -216.954 | -381.741 | -10.663 | -5.061 |
| Income Before Tax Ratio
| -25.703 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -25.056 | -0.747 | 0.114 | 0.378 | 0.223 |
| Net Income
| -151.085 | -216.207 | -381.854 | -11.041 | -5.284 |
| Net Income Ratio
| -22.047 | 0 | 0 | 0 | 0 |
| EPS
| -1.57 | -2.31 | -4.24 | -0.078 | -0.075 |
| EPS Diluted
| -1.57 | -2.31 | -4.24 | -0.078 | -0.075 |
| EBITDA
| -166.066 | -212.263 | -379.158 | -10.434 | -4.937 |
| EBITDA Ratio
| -24.233 | 0 | 0 | 0 | 0 |